Pharmacokinetics and relative bioavailability of Sparfloxacin in healthy volunteer
-
摘要: 目的 建立测定血浆中司帕沙星的HPLC内标法并研究司帕沙星片的相对生物利用度及生物等效性。 方法 20名健康志愿者分两组,随机、交叉口服受试制剂与参比制剂的司帕沙星片0.4 g,HPLC法测定血药浓度,计算药动学参数及生物等效性评价。 结果 受试制剂与参比制剂血浆中司帕沙星的tmax为(4.68±0.44)和(4.55±0.51)h;Cmax为(1 560.4±243.9)和(1 584.1±273.9)ng/ml;t1/2为(20.92±4.85)和 (19.81±3.75)h;用梯形法计算AUC0-t为(43 325±12 174)和(44 139±11 815)ng·h/ml;AUC0-∞为(45 452±12 884)和(45 999±12 629)ng·h/ml。以AUC0-t计算,受试制剂的平均相对生物利用度为(97.9±5.8)%。 结论 两制剂具有生物等效性。Abstract: Objective To determine Sparfloxacin concentrations in human plasma and study the pharmacokinetics and relative bioavailability of Sparfloxacin for Suspension. Methods A single dose reference and test was given to 20 healthy volunteers in a randomized 2-way cross-over study. The plasma Sparfloxacin concentrations were determined by HPLC. The pharmacokinetics as well as relative bioavailability was measured. Results The main pharmacokinetic parameters of two formulations, Sparfloxacin in test and reference drug were as follows:tmax were (4.68±0.44)and(4.55±0.51)h;Cmax were(1 560.4±243.9)and(1 584.1±273.9)ng/ml;t1/2 were(20.92±4.85)and (19.81±3.75)h;AUC0-t were (43 325±12 174)and(44 139±11 815)ng·h/ml;AUC0-∞ were(45 452±12 884)and(45 999±12 629)ng·h/ml respectively. Using DASS program, the results of variance and two one-sided t-test statistical analyses for Ln Cmax. Two formulations were bioequivalent. Conclusion The reference and test Sparfloxacin were bioequivalent.
-
Key words:
- Sparfloxacin /
- bioavailability /
- bioequivalence /
- HPLC
-
[1] 中国药典2005版.二部[S]. 2005,附录173. [2] 中国药典2005版.二部[S]. 2005,161. [3] 钟大放. 以加权最小二乘法建立生物分析标准曲线的若干问题[J]. 药物分析杂志,2006,16(5):343. [4] 梁竹,潘菡清,袁成,等. 高效液相色谱法测定血清和尿中司帕沙星的药物浓度[J]. 解放军药学学报, 2005,15(3):40. [5] 张毕奎,杨宇,李焕德,等. 国产司帕沙星片在老年人体内的药动学研究[J]. 临床药学,2008,37(2):120. -
![WeChat](/fileYXSJZZ/journal/article/yxsjzz/2012/5/PIC/wechat_cn_20120515.jpg)
计量
- 文章访问数: 2465
- HTML全文浏览量: 273
- PDF下载量: 338
- 被引次数: 0